GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kineta Inc (OTCPK:KANT) » Definitions » Enterprise Value

KANT (Kineta) Enterprise Value : $9.74 Mil (As of Dec. 15, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Kineta Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Kineta's Enterprise Value is $9.74 Mil. Kineta's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $-20.46 Mil. Therefore, Kineta's EV-to-EBIT ratio for today is -0.48.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Kineta's Enterprise Value is $9.74 Mil. Kineta's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was $-20.45 Mil. Therefore, Kineta's EV-to-EBITDA ratio for today is -0.48.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Kineta's Enterprise Value is $9.74 Mil. Kineta's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil. Therefore, Kineta's EV-to-Revenue ratio for today is .


Kineta Enterprise Value Historical Data

The historical data trend for Kineta's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kineta Enterprise Value Chart

Kineta Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Enterprise Value
- - 51.25 35.83

Kineta Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.82 34.15 41.81 5.49 6.48

Competitive Comparison of Kineta's Enterprise Value

For the Biotechnology subindustry, Kineta's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kineta's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kineta's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Kineta's Enterprise Value falls into.



Kineta Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Kineta's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Kineta's Enterprise Value for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kineta  (OTCPK:KANT) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Kineta's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=9.743/-20.458
=-0.48

Kineta's current Enterprise Value is $9.74 Mil.
Kineta's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.46 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Kineta's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=9.743/-20.453
=-0.48

Kineta's current Enterprise Value is $9.74 Mil.
Kineta's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.45 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Kineta's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=9.743/0
=

Kineta's current Enterprise Value is $9.74 Mil.
Kineta's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kineta Enterprise Value Related Terms

Thank you for viewing the detailed overview of Kineta's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Kineta Business Description

Traded in Other Exchanges
Address
7683 SE 27th Street, Suite 481, Mercer Island, WA, USA, 98040
Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's asset is KVA12.1, a VISTA blocking immunotherapy.
Executives
Raymond J. Bartoszek director C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Shawn Iadonato director, officer: Chief Executive Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Craig W. Philips officer: President C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Pauline Kenny officer: General Counsel C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Keith Baker officer: Chief Financial Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Thierry Guillaudeux officer: Chief Scientific Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Scott J. Dylla director C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Marion R Foote director C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Michael D Wyzga officer: See Remarks C/O YUMANITY, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Devin Whittemore Smith officer: SVP and General Counsel C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Kimberlee C Drapkin director PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ajay Verma officer: EVP, Head of R&D C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Lynne Zydowsky director C/O YUMANITY THERAPEUTICS, INC., 40 GUEST STREET, BOSTON MA 02135
Susan L. Lindquist Exempt Marital Trust 10 percent owner C/O NANCY E. DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109
Susan L. Lindquist Massachusetts Non-exempt Marital Trust 10 percent owner C/O NANCY DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109